The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

You are here: Home / Archives for Webinar

Join us for our next webinar on Thursday June 6th!

by

Registration is open!

In this webinar Dr. Jin Lu will show how Lonza’s novel GS Discovery® transient expression platform can boost transient titers by ~30-fold to enable rapid early material supply, and streamline the transition from discovery to stable production. Dr. Lu will also introduce bYlok® bispecific pairing technology – an innovative solution that drives correct heavy-light chain pairing rates in IgG-like bispecifics to >95%. This improves yields of the correct species and streamlines downstream processing, without affecting key performance attributes of the molecule. Dr. Lu will present the latest case studies of bYlok® engineered bispecifics and explore how bYlok® compares to other established pairing solutions.

Join us on April 25 to learn how to harness divergent species to access difficult and conserved antibody targets!

by

Registration is open!

To exploit highly conserved and difficult drug targets, including GPCRs and ion channels, monoclonal antibody discovery efforts are increasingly relying on the advantages offered by divergent species such as rabbits, camelids, and chickens. Divergent host species enable robust immune responses against highly conserved binding sites and yield antibodies capable of penetrating functional pockets via long HCDR3 regions. Pan-reactive molecules are often produced by divergent hosts, and these antibodies can be tested in accessible animal models, offering a faster path to clinical development. In this webinar, Dr. Ross Chambers will analyze gaps in therapeutic antibodies that stem from the historic use of mice and examine opportunities to exploit previously inaccessible targets through discovery in alternate species. Examples of preclinical and clinical-stage antibodies raised in divergent species will be highlighted, providing an overview of their success.

The Nov 7th AIRR-C webinar is now available online

by

The last AIRR-C webinar “Quality Control Pipelines for T cell and B cell AIRR-seq”, by Dr. Encarnita Mariotti-Ferrandiz (Sorbonne Universite) and Dr. Nina Luning Prak (University of Pennsylvania) is now available online. 

Visit the AIRR Community Webinar Series website to learn more about this series and access the recordings of past sessions.

Join us for the next AIRR-C webinar on Dec 7th!

by

Explore with us the state-of-the-art in TCR-Epitope prediction. T-cells are at the heart of the immune system’s ability to distinguish between self and non-self, playing a critical role in both health and disease. Given the sheer scale of potential TCR-epitope interactions (stemming from both the enormous epitope and TCR repertoire diversity) experimental validation of each TCR interaction is not feasible. This has spurred the development of TCR-epitope prediction models that aim to narrow down the search for immunogenic epitopes, thereby streamlining research and reducing costs. Our webinar “Exploring TCR-Epitope Prediction Tools: Insights and Pitfalls” will delve into these predictive strategies, highlighting their importance in advancing immunological research and applications.

Speakers:

  • Dr. Kerry Mullan (University of Antwerp, Belgium) 
  • Vincent Van Deuren (University of Antwerp, Belgium) 
  • Romi Vandoren (University of Antwerp, Belgium) 

All three researchers are working under the supervision of Prof. Pieter Meysman, Prof. Kris Laukens, and Prof. Benson Ogunjimi at the University of Antwerp in Belgium.

Registration is open. Visit the AIRR Community Webinar Series website to learn more about this series and access the recordings of past sessions.

Wondering which Antibodies to Watch in 2023?

by

Join us for our next webinar to learn which late-stage antibodies you should watch next year!

Registration is open!

Antibodies to Watch in 2023

 

Thursday January 12, 2023, 11am ET / 4pm CET

Speakers: Drs. Janice Reichert, Silvia Crescioli, Alicia Chenoweth & Jyothsna Visweswaraiah

“Antibodies to Watch in 2023” highlights key events in commercial monoclonal antibody therapeutics development that occurred in 2022 and forecasts events that might occur in 2023. In this presentation, we will discuss the antibody therapeutics granted first approvals in either the United States or European Union in 2022, which include 4 bispecific antibodies ((tebentafusp, faricimab, mosunetuzumab and teclistamab) and 1 ADC (mirvetuximab soravtansine). We will also discuss approvals for antibody therapeutics that were first granted in China or Japan in 2022, which include 2 bispecific antibodies (cadonilimab and ozoralizumab). Globally, at least 24 investigational antibody therapeutics are undergoing review by regulatory agencies. Our data show that, with antibodies for COVID-19 excluded, the late-stage commercial clinical pipeline grew by ~20% in the past year to include nearly 140 investigational antibody therapeutics that were designed using a wide variety of formats and engineering techniques. Of those in late-stage development, marketing application submissions for at least 23 may occur by the end of 2023, of which 5 are bispecific (odronextamab, erfonrilimab, linvoseltamab, zanidatamab, and talquetamab) and 2 are ADCs (datopotamab deruxtecan, and tusamitamab ravtansine).

Everyone who registers will receive 3 reminders before the event, as well as the link to the On Demand version when it is available.

Registration is open!